Top

memo - Magazine of European Medical Oncology

Published in:

Open Access 01-03-2019 | short review

Therapeutic endoscopic strategies in early esophageal cancer and dysplastic Barrett’s epithelium

Authors: Teresa Fritz, Rainer Schöfl, Friedrich Wewalka, Alexander Ziachehabi

Published in: memo - Magazine of European Medical Oncology | Issue 1/2019

Summary

Endoscopic therapy is the gold standard for curative treatment of early esophageal adenocarcinoma (EAC) including dysplastic Barrett´s epithelium (BE) and very early squamous cell carcinoma (SCC) because it is superior to surgery in regard to morbidity, mortality and cost effectiveness while yielding excellent results and low complication rates.

Tumor detection at an early stage is often challenging and a multimodal approach using high resolution white light endoscopy, virtual chromoendoscopy (e.g. narrow band imaging, NBI) and endoscopic ultrasonography (EUS) is recommended. Importantly, histological diagnosis and EUS guided tumor staging should be performed before endoscopic tumor resection, although EUS validity has its limitations in terms of superficial mucosal and submucosal tumor invasion.

In early esophageal adenocarcinoma, endoscopic mucosal resection (EMR) is considered the first line therapy and endoscopic submucosal dissection (ESD) is recommended only in special cases. In contrast, in very early squamous cell carcinoma, ESD is superior to EMR. This is mainly caused by a lower risk for lymphatic metastases in adenocarcinoma compared to squamous cell carinoma. If endoscopic resection is not curative or not feasible, surgery is the treatment of choice - assuming the patient´s comorbidities and performance status are no exclusion criteria.

Bailey SH, et al. Outcomes after esophagectomy: a ten-year prospective cohort. Ann Thorac Surg. 2003;75(1):217–22. discussion 222.PubMedCrossRef

Rosenberg N. Submucosal saline wheal as safety factor in fulguration or rectal and sigmoidal polypi. AMA Arch Surg. 1955;70(1):120–2.PubMedCrossRef

Yahagi N, Fujishiro M, Kakushima N, Kobayashi K, Hashimoto T, Oka M, Iguchi M, Enomoto S, Ichinose M, Niwa H, Omata M. Endoscopic submucosal dissection for early gastric cancer using the tip of an electrosurgical snare (thin type). Dig Endosc. 2004;16:34–8.CrossRef

Ono H, et al. Endoscopic mucosal resection for treatment of early gastric cancer. Gut. 2001;48(2):225–9.PubMedPubMedCentralCrossRef

Lian J, et al. A meta-analysis of endoscopic submucosal dissection and EMR for early gastric cancer. Gastrointest Endosc. 2012;76(4):763–70.PubMedCrossRef

Park YM, et al. The effectiveness and safety of endoscopic submucosal dissection compared with endoscopic mucosal resection for early gastric cancer: a systematic review and metaanalysis. Surg Endosc. 2011;25(8):2666–77.PubMedCrossRef

Ahlenstiel G, et al. Actual endoscopic versus predicted surgical mortality for treatment of advanced mucosal neoplasia of the colon. Gastrointest Endosc. 2014;80(4):668–76.PubMedCrossRef

Jayanna M, et al. Cost analysis of endoscopic mucosal resection vs surgery for large laterally spreading colorectal lesions. Clin Gastroenterol Hepatol. 2016;14(2):271–278e1–2.PubMedCrossRef

Thomas T, et al. High-resolution endoscopy and endoscopic ultrasound for evaluation of early neoplasia in Barrett’s esophagus. Surg Endosc. 2010;24(5):1110–6.PubMedCrossRef

10.

Puli SR, et al. Staging accuracy of esophageal cancer by endoscopic ultrasound: a meta-analysis and systematic review. World J Gastroenterol. 2008;14(10):1479–90.PubMedPubMedCentralCrossRef

11.

Scotiniotis IA, et al. Accuracy of EUS in the evaluation of Barrett’s esophagus and high-grade dysplasia or intramucosal carcinoma. Gastrointest Endosc. 2001;54(6):689–96.PubMedCrossRef

12.

Peters FP, et al. Histologic evaluation of resection specimens obtained at 293 endoscopic resections in Barrett’s esophagus. Gastrointest Endosc. 2008;67(4):604–9.PubMedCrossRef

13.

The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. Gastrointest Endosc, 2003. 58(6): p. S3–S43.

14.

Gono K, Yamazaki K, Doguchi N, Nonami T, Obi T, Yamaguchi M, Ohyama N, Machida H, Sano Y, Yoshida S, Hamamoto Y, Endo T. Endoscopic Observation of Tissue by Narrowband Illumination. Opt Rev. 2003;10(4):211–5.CrossRef

15.

Sato H, et al. Utility of intrapapillary capillary loops seen on magnifying narrow-band imaging in estimating invasive depth of esophageal squamous cell carcinoma. Endoscopy. 2015;47(2):122–8.PubMedCrossRef

16.

Mizumoto T, et al. Magnifying endoscopy with narrow band imaging in estimating the invasion depth of superficial esophageal squamous cell carcinomas. Digestion. 2018;98(4):249–56.PubMedCrossRef

17.

Endoscopic Classification Review G. Update on the paris classification of superficial neoplastic lesions in the digestive tract. Endoscopy. 2005;37(6):570–8.CrossRef

18.

Sharma P, et al. Development and validation of a classification system to identify high-grade dysplasia and esophageal adenocarcinoma in Barrett’s esophagus using narrow-band imaging. Baillieres Clin Gastroenterol. 2016;150(3):591–8.

19.

Kandiah K, et al. International development and validation of a classification system for the identification of Barrett’s neoplasia using acetic acid chromoendoscopy: the Portsmouth acetic acid classification (PREDICT). Gut. 2017; https://doi.org/10.1136/gutjnl-2017-314512.PubMedCrossRef

20.

Larghi A, et al. EUS followed by EMR for staging of high-grade dysplasia and early cancer in Barrett’s esophagus. Gastrointest Endosc. 2005;62(1):16–23.PubMedCrossRef

21.

Dubecz A, et al. Does the incidence of adenocarcinoma of the esophagus and gastric cardia continue to rise in the twenty-first century?—a SEER database analysis. J Gastrointest Surg. 2013;18:124. https://doi.org/10.1007/s11605-013-2345-8.CrossRef

22.

Desai TK, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett’s oesophagus: a meta-analysis. Gut. 2012;61(7):970–6.PubMedCrossRef

23.

Weusten B, et al. Endoscopic management of Barrett’s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy. 2017;49(2):191–8.PubMedCrossRef

24.

Bhat SK, et al. Oesophageal adenocarcinoma and prior diagnosis of Barrett’s oesophagus: a population-based study. Gut. 2015;64(1):20–5.PubMedCrossRef

25.

Dulai GS, et al. Preoperative prevalence of Barrett’s esophagus in esophageal adenocarcinoma: a systematic review. Baillieres Clin Gastroenterol. 2002;122(1):26–33.

26.

Pimentel-Nunes P, et al. Endoscopic submucosal dissection: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2015;47(9):829–54.PubMedCrossRef

27.

Duits LC, et al. Barrett’s oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel. Gut. 2015;64(5):700–6.PubMedCrossRef

28.

Inoue H. Endoscopic mucosal resection for the entire gastrointestinal mucosal lesions. Gastrointest Endosc Clin N Am. 2001;11(3):459–78.PubMedCrossRef

29.

Seewald S, et al. Circumferential EMR and complete removal of Barrett’s epithelium: a new approach to management of Barrett’s esophagus containing high-grade intraepithelial neoplasia and intramucosal carcinoma. Gastrointest Endosc. 2003;57(7):854–9.PubMedCrossRef

30.

Abrams JA, et al. Depth of resection using two different endoscopic mucosal resection techniques. Endoscopy. 2008;40(5):395–9.PubMedPubMedCentralCrossRef

31.

May A, et al. A prospective randomized trial of two different endoscopic resection techniques for early stage cancer of the esophagus. Gastrointest Endosc. 2003;58(2):167–75.PubMedCrossRef

32.

Pouw RE, et al. Randomized trial on endoscopic resection-cap versus multiband mucosectomy for piecemeal endoscopic resection of early Barrett’s neoplasia. Gastrointest Endosc. 2011;74(1):35–43.PubMedCrossRef

33.

Pech O, et al. Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus. Baillieres Clin Gastroenterol. 2014;146(3):652–660e1.

34.

Phoa KN, et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA. 2014;311(12):1209–17.PubMedCrossRef

35.

Shaheen NJ, et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med. 2009;360(22):2277–88.PubMedCrossRef

36.

Small AJ, et al. Radiofrequency ablation is associated with decreased neoplastic progression in patients with Barrett’s esophagus and confirmed low-grade dysplasia. Baillieres Clin Gastroenterol. 2015;149(3):567–576e3. quiz e13–4.

37.

Shaheen NJ, et al. Durability of radiofrequency ablation in Barrett’s esophagus with dysplasia. Baillieres Clin Gastroenterol. 2011;141(2):460–8.

38.

Pech O, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett’s oesophagus. Gut. 2008;57(9):1200–6.PubMedCrossRef

39.

Griffin SM, Burt AD, Jennings NA. Lymph node metastasis in early esophageal adenocarcinoma. Ann Surg. 2011;254(5):731–6. discussion 736–7.PubMedCrossRef

40.

Zemler B, et al. Early Barrett’s carcinoma: the depth of infiltration of the tumour correlates with the degree of differentiation, the incidence of lymphatic vessel and venous invasion. Virchows Arch. 2010;456(6):609–14.PubMedCrossRef

41.

Gamboa AM, et al. Treatment allocation in patients with early-stage esophageal adenocarcinoma: prevalence and predictors of lymph node involvement. Cancer. 2016;122(14):2150–7.PubMedCrossRef

42.

Manner H, et al. Efficacy, safety, and long-term results of endoscopic treatment for early stage adenocarcinoma of the esophagus with low-risk sm1 invasion. Clin Gastroenterol Hepatol. 2013;11(6):630–5. quiz e45.PubMedCrossRef

43.

Terheggen G, et al. A randomised trial of endoscopic submucosal dissection versus endoscopic mucosal resection for early Barrett’s neoplasia. Gut. 2017;66(5):783–93.PubMedCrossRef

44.

Cao Y, et al. Meta-analysis of endoscopic submucosal dissection versus endoscopic mucosal resection for tumors of the gastrointestinal tract. Endoscopy. 2009;41(9):751–7.PubMedCrossRef

45.

Morita FH, et al. Narrow band imaging versus lugol chromoendoscopy to diagnose squamous cell carcinoma of the esophagus: a systematic review and meta-analysis. BMC Cancer. 2017;17(1):54.PubMedPubMedCentralCrossRef

46.

Inoue H, et al. Magnification endoscopy in esophageal squamous cell carcinoma: a review of the intrapapillary capillary loop classification. Ann Gastroenterol. 2015;28(1):41–8.PubMedPubMedCentral

47.

Takahashi H, et al. Endoscopic submucosal dissection is superior to conventional endoscopic resection as a curative treatment for early squamous cell carcinoma of the esophagus (with video). Gastrointest Endosc. 2010;72(2):255–264, 264e1–2.PubMedCrossRef

48.

Tajima Y, et al. Significance of involvement by squamous cell carcinoma of the ducts of esophageal submucosal glands. Analysis of 201 surgically resected superficial squamous cell carcinomas. Cancer. 2000;89(2):248–54.PubMedCrossRef

49.

Natsugoe S, et al. Mucosal squamous cell carcinoma of the esophagus: a clinicopathologic study of 30 cases. Oncology. 1998;55(3):235–41.PubMedCrossRef

50.

Bollschweiler E, et al. High rate of lymph-node metastasis in submucosal esophageal squamous-cell carcinomas and adenocarcinomas. Endoscopy. 2006;38(2):149–56.PubMedCrossRef

51.

Yang D, et al. Endoscopic submucosal dissection for early Barrett’s neoplasia: a meta-analysis. Gastrointest Endosc. 2018;87(6):1383–93.PubMedCrossRef

52.

Ono S, et al. Predictors of postoperative stricture after esophageal endoscopic submucosal dissection for superficial squamous cell neoplasms. Endoscopy. 2009;41(8):661–5.PubMedCrossRef

53.

Yamaguchi N, et al. Usefulness of oral prednisolone in the treatment of esophageal stricture after endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma. Gastrointest Endosc. 2011;73(6):1115–21.PubMedCrossRef

54.

Hashimoto S, et al. The efficacy of endoscopic triamcinolone injection for the prevention of esophageal stricture after endoscopic submucosal dissection. Gastrointest Endosc. 2011;74(6):1389–93.PubMedCrossRef

55.

Deprez PH. Esophageal strictures after extensive endoscopic resection: hope for a better outcome? Gastrointest Endosc. 2013;78(2):258–9.PubMedCrossRef

56.

Kuribayashi Y, et al. Esophageal motility after extensive circumferential endoscopic submucosal dissection for superficial esophageal cancer. Digestion. 2018;98(3):153–60.PubMedCrossRef

Title: Therapeutic endoscopic strategies in early esophageal cancer and dysplastic Barrett’s epithelium
Authors: Teresa Fritz
Rainer Schöfl
Friedrich Wewalka
Alexander Ziachehabi
Publication date: 01-03-2019
Publisher: Springer Vienna
Published in: memo - Magazine of European Medical Oncology / Issue 1/2019
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-018-0461-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 1/2019

Educational no. 4: PCR-based methods

The path of an esophageal carcinoma patient from curative to palliative treatment

Diffuse large B‑cell lymphoma

Demystification of palliative care. In regard to Masel and Kreye

Role of immune checkpoint inhibitors in gastrointestinal cancer treatment

An update on immunotherapy in breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer